Janus Henderson Group PLC Igm Biosciences, Inc. Transaction History

Janus Henderson Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$57.98 - $96.6 $15.6 Million - $26 Million	-268,933 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$71.56 - $121.23 $16.7 Million - $28.2 Million	-232,812 Reduced 46.4%	268,933 $20.6 Million
Q4 2020 Feb 16, 2021	SELL	$47.41 - $115.03 $16.3 Million - $39.5 Million	-343,190 Reduced 40.62%	501,745 $44.3 Million
Q3 2020 Nov 16, 2020	SELL	$43.0 - $84.01 $3.54 Million - $6.92 Million	-82,415 Reduced 8.89%	844,935 $62.4 Million
Q2 2020 Aug 14, 2020	SELL	$51.3 - $75.21 $28.3 Million - $41.5 Million	-551,455 Reduced 37.29%	927,350 $67.7 Million
Q1 2020 May 14, 2020	SELL	$31.51 - $73.75 $1.42 Million - $3.32 Million	-44,957 Reduced 2.95%	1,478,805 $79.8 Million
Q4 2019 Feb 18, 2020	BUY	$17.25 - $49.51 $17.2 Million - $49.4 Million	997,235 Added 189.4%	1,523,762 $56 Million
Q3 2019 Nov 14, 2019	BUY	$17.75 - $24.3 $9.35 Million - $12.8 Million	526,527 New	526,527 $9.35 Million

20.7M

68K

52.2K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $275M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.